Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Keefe RS, Fox KH, Harvey PD, Cucchiaro J, Siu C, Loebel A.

Schizophr Res. 2011 Feb;125(2-3):161-8. doi: 10.1016/j.schres.2010.09.015. Epub 2010 Dec 31.

PMID:
21075600
2.

[Short-term efficacy and safety of lurasidone in the treatment of schizophrenia].

Samalin L, Ben Gharbia M, Garnier M, Llorca PM.

Encephale. 2014 Dec;40(6):507-17. Review. French.

PMID:
25453735
3.

Update on the development of lurasidone as a treatment for patients with acute schizophrenia.

Yasui-Furukori N.

Drug Des Devel Ther. 2012;6:107-15. doi: 10.2147/DDDT.S11180. Epub 2012 May 8. Review.

4.

[Cognitive deficit in schizophrenia: MATRICS Consensus Cognitive Battery].

Rodríguez-Jiménez R, Bagney A, Moreno-Ortega M, García-Navarro C, Aparicio AI, López-Antón R, de la Oliva J, Jiménez-Arriero MÁ, Santos JL, Lobo A, Palomo T.

Rev Neurol. 2012 Nov 1;55(9):549-55. Review. Spanish.

5.

The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC).

Yatham LN, Torres IJ, Malhi GS, Frangou S, Glahn DC, Bearden CE, Burdick KE, Martínez-Arán A, Dittmann S, Goldberg JF, Ozerdem A, Aydemir O, Chengappa KN.

Bipolar Disord. 2010 Jun;12(4):351-63. doi: 10.1111/j.1399-5618.2010.00830.x. Review.

PMID:
20636632
6.

Lurasidone: a new treatment option for schizophrenia.

Owen RT.

Drugs Today (Barc). 2011 Nov;47(11):807-16. doi: 10.1358/dot.2011.47.11.1708832. Review.

PMID:
22146224
7.

Use of the MATRICS consensus cognitive battery (MCCB) to evaluate cognitive deficits in bipolar disorder: A systematic review and meta-analysis.

Bo Q, Mao Z, Li X, Wang Z, Wang C, Ma X.

PLoS One. 2017 Apr 24;12(4):e0176212. doi: 10.1371/journal.pone.0176212. eCollection 2017. Review.

8.

Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?

Keefe RS, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M.

Schizophr Bull. 2013 Mar;39(2):417-35. doi: 10.1093/schbul/sbr153. Epub 2011 Nov 22. Review.

9.

Cognitive impairment as a target for pharmacological treatment in schizophrenia.

Davidson M, Keefe RS.

Schizophr Res. 1995 Sep;17(1):123-9. Review. No abstract available.

PMID:
8541245
10.
11.

[Research progress in mechanisms and clinical application for blonanserin and lurasidone in improving cognitive function of schizophrenia].

Zheng Q, Liu B, Xu S, Liao M, Zhang Y, Li L.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Apr 28;42(4):476-480. doi: 10.11817/j.issn.1672-7347.2017.04.018. Review. Chinese.

12.

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.

Keefe RS, Haig GM, Marder SR, Harvey PD, Dunayevich E, Medalia A, Davidson M, Lombardo I, Bowie CR, Buchanan RW, Bugarski-Kirola D, Carpenter WT, Csernansky JT, Dago PL, Durand DM, Frese FJ, Goff DC, Gold JM, Hooker CI, Kopelowicz A, Loebel A, McGurk SR, Opler LA, Pinkham AE, Stern RG.

Schizophr Bull. 2016 Jan;42(1):19-33. doi: 10.1093/schbul/sbv111. Epub 2015 Sep 11.

13.

Animal models of schizophrenia.

Jones CA, Watson DJ, Fone KC.

Br J Pharmacol. 2011 Oct;164(4):1162-94. doi: 10.1111/j.1476-5381.2011.01386.x. Review.

14.

Neurocognitive impairment in schizophrenia and how it affects treatment options.

Bilder RM.

Can J Psychiatry. 1997 Apr;42(3):255-64. Review.

PMID:
9114941
15.

Direct assessment of functional abilities: relevance to persons with schizophrenia.

McKibbin CL, Brekke JS, Sires D, Jeste DV, Patterson TL.

Schizophr Res. 2004 Dec 15;72(1):53-67. Review.

PMID:
15531407
16.

Newer antipsychotics and upcoming molecules for schizophrenia.

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA.

Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. Review.

PMID:
23545936
17.

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA.

Pharmacol Ther. 2009 May;122(2):150-202. doi: 10.1016/j.pharmthera.2009.02.004. Epub 2009 Mar 6. Review.

18.

Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.

Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R.

Biol Psychiatry. 2008 Jul 1;64(1):4-10. doi: 10.1016/j.biopsych.2008.03.020. Epub 2008 May 7.

19.

The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.

Hvoslef-Eide M, Mar AC, Nilsson SR, Alsiö J, Heath CJ, Saksida LM, Robbins TW, Bussey TJ.

Psychopharmacology (Berl). 2015 Nov;232(21-22):3853-72. doi: 10.1007/s00213-015-4007-x. Epub 2015 Jul 24. Review.

PMID:
26202612
20.

Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.

Goldberg TE, Keefe RS, Goldman RS, Robinson DG, Harvey PD.

Neuropsychopharmacology. 2010 Apr;35(5):1053-62. doi: 10.1038/npp.2009.211. Epub 2010 Jan 20. Review.

Supplemental Content

Support Center